Medtronic Plc (MDT) remains a top pick for
Goldman Sachs Fund Managers and continues to attract investor interest despite underperforming in the market compared to its competitors. Some concerns have been raised over MDT's financials as multiple entities are reducing their stock holdings, including
Bard Financial Services and
Clearbridge Investments. This has led analysts to question the stock's upward trend amidst weak financial prospects. On the operational front, Medtronic issued a recall for its
MiniMed insulin pumps due to battery issues but successfully announced the pricing of €3.0 billion of senior notes.
Positive trial outcomes for PulseSelect PFA boost potential for MDT's stock. The company has announced a cash dividend for the second quarter of fiscal year 2025 and sees its Cardiovascular business expand amid macro woes. However, its shares sank in the market, moving -1.04% recently. Medtronic is due to announce financial results for its third quarter of fiscal year 2024, and investors already have their sights set on early projections of Q1 2025 earnings. Growing approval of Medtronic's novel devices like the
Simplera™ CGM and
Inceptiv™ spinal cord stimulator indicate a continued trend of innovation. Their Q4 earnings showcased strong sales from neurology devices.
Medtronic Plc MDT News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sat, 05 Oct 2024 22:21:46 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor 2
